Molecular Pharmaceutics最新文献

筛选
英文 中文
Theoretical Quantification of Cargo Effective Diffusivity in Affinity-Based Hydrogels 亲和型水凝胶中货物有效扩散系数的理论量化
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-10-18 DOI: 10.1021/acs.molpharmaceut.6c00188
Ruhanesh Suthan, Ian Keen Koo, Xin Wang, K. B. Goh
{"title":"Theoretical Quantification of Cargo Effective Diffusivity in Affinity-Based Hydrogels","authors":"Ruhanesh Suthan,&nbsp;Ian Keen Koo,&nbsp;Xin Wang,&nbsp;K. B. Goh","doi":"10.1021/acs.molpharmaceut.6c00188","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00188","url":null,"abstract":"<p>Affinity hydrogels enable precise control of cargo release kinetics through specific, non-covalent interactions between the functionalized polymer network and therapeutic agents. Yet, how these interactions integrate with steric hindrance in the crosslinked network to determine cargo diffusivity, a critical kinetic parameter governing cargo-controlled release, remains poorly quantified. Here, we present a theoretical framework that explicitly bridges microscopic cargo−polymer interactions with macroscopic cargo release kinetics. Specifically, our approach delineates cargo diffusivity into two principal contributions: (i) binding interactions and (ii) steric hindrance, enabling a quantitative understanding of their interplay in defining cargo release performance. Increasing binding interactions, attractively, reduce diffusivity in a reverse sigmoidal fashion, transitioning from a steric- to a binding-controlled regime. Overall, we demonstrate how the interplay of microscopic forces governs cargo diffusivity within affinity hydrogels and, in turn, regulates cumulative cargo release at the macroscopic level, thereby bridging microscopic thermodynamic interactions with macroscopic cargo release kinetics, quantitatively.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5261–5271"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fatty Acids for the Treatment of Ocular Diseases and Ocular Drug Delivery 脂肪酸用于眼部疾病的治疗和眼部药物输送
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-10-18 DOI: 10.1021/acs.molpharmaceut.6c00705
Guihua Fang, Bo Tang, Jiayan Yin
{"title":"Fatty Acids for the Treatment of Ocular Diseases and Ocular Drug Delivery","authors":"Guihua Fang,&nbsp;Bo Tang,&nbsp;Jiayan Yin","doi":"10.1021/acs.molpharmaceut.6c00705","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00705","url":null,"abstract":"<p>The intricate anatomical and physiological barriers of the eye severely limit the bioavailability of conventional topical therapies, necessitating innovative strategies. In this review, fatty acids are presented as versatile agents functioning in two distinct roles. As bioactive lipids, specific fatty acids exert disease-modifying effects, offering novel pharmacological interventions for ocular surface and posterior segment disorders, including dry eye syndrome, uveitis, and retinal degeneration. Concurrently, beyond their biological activity, fatty acids serve as structural components in formulation design; their physicochemical properties, particularly varying chain lengths and degrees of unsaturation, enable the construction of advanced ocular drug delivery systems with substantially enhanced ocular bioavailability. Crucially, this review not only summarizes the translational prospects of fatty acid-based therapeutics but also highlights the structure−activity relationships governing the in vivo performance of fatty acid-integrated delivery systems. By delineating these dual functionalities, we provide a clear framework for distinguishing nutritional or pharmacological supplementation from excipient or carrier design, thereby facilitating the rational development of next-generation ophthalmic formulations.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5197–5215"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First-in-Human PET/CT Imaging of FXX489, a Second-Generation Cyclic Peptide FAP Inhibitor: A Translational Exploratory Study 第二代环肽FAP抑制剂FXX489的首次人体PET/CT成像:一项转化探索性研究
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-09-25 DOI: 10.1021/acs.molpharmaceut.6c00763
Yi Tian, Leyi Ying, Yuxiang Wang, Shu Wang, Xuefei Li, Yaming Li, Xuena Li
{"title":"First-in-Human PET/CT Imaging of FXX489, a Second-Generation Cyclic Peptide FAP Inhibitor: A Translational Exploratory Study","authors":"Yi Tian,&nbsp;Leyi Ying,&nbsp;Yuxiang Wang,&nbsp;Shu Wang,&nbsp;Xuefei Li,&nbsp;Yaming Li,&nbsp;Xuena Li","doi":"10.1021/acs.molpharmaceut.6c00763","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00763","url":null,"abstract":"<p>Sufficient tumor uptake and retention, and high tumor-to-kidney ratio are highly relevant for fibroblast activation protein (FAP)-targeted tracers as imaging companions for theranostic development. Although FAP-2286 improves tumor retention versus early-generation FAPI tracers, its extended renal residence limits its application as a radiopharmaceutical therapy. We benchmarked FXX489, a next-generation cyclic peptide FAP ligand, against FAP-2286 preclinically and evaluated first-in-human [<sup>68</sup>Ga]Ga-FXX489 PET/CT to support its translational development for FAP-directed theranostics. [<sup>68</sup>Ga]Ga-FXX489 showed stronger FAP affinity than [<sup>68</sup>Ga]Ga-FAP-2286, including higher cellular uptake, lower efflux, and lower IC<sub>50</sub>. In HT-1080-hFAP xenografts, [<sup>68</sup>Ga]Ga-FXX489 achieved higher tumor uptake and retention on micro-PET and ex vivo biodistribution, and a higher tumor-to-kidney ratio. In patients (<em>n</em> = 10), [<sup>68</sup>Ga]Ga-FXX489 was well tolerated, and detected all 12 primary lesions (mean SUVmax, 11.20 ± 3.24) and all 42 metastatic lymph nodes (100% [42/42] vs 74% [31/42] for [<sup>18</sup>F]FDG, <em>P</em> &lt; 0.001), while visualizing gastric cancer lesions with higher uptake than [<sup>18</sup>F]FDG in a paired comparison. [<sup>68</sup>Ga]Ga-FXX489 improves tumor retention and tumor-to-kidney ratio compared to [<sup>68</sup>Ga]Ga-FAP-2286 while maintaining specific FAP targeting. First-in-human [<sup>68</sup>Ga]Ga-FXX489 PET/CT shows promising detection of primary and metastatic lesions, supporting further clinical applications.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5630–5641"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A γ-AApeptide-Based Antibody-like Peptidomimetic for Enhanced EGFR-Targeted PET Imaging 一种基于γ- a肽的抗体样拟肽增强egfr靶向PET成像
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-09-29 DOI: 10.1021/acs.molpharmaceut.6c00810
Xiaoyan Li, Yu Yu Win, Yuan Hua, Muhammad Amir, Jason C. Mixdorf, Jonathan W. Engle, Todd E. Barnhart, Yu Zhou, Weibo Cai
{"title":"A γ-AApeptide-Based Antibody-like Peptidomimetic for Enhanced EGFR-Targeted PET Imaging","authors":"Xiaoyan Li,&nbsp;Yu Yu Win,&nbsp;Yuan Hua,&nbsp;Muhammad Amir,&nbsp;Jason C. Mixdorf,&nbsp;Jonathan W. Engle,&nbsp;Todd E. Barnhart,&nbsp;Yu Zhou,&nbsp;Weibo Cai","doi":"10.1021/acs.molpharmaceut.6c00810","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00810","url":null,"abstract":"<p>Targeted imaging for the extracellular domain (ECD) of epidermal growth factor receptor (EGFR) is promising for early diagnosis and therapeutic applications toward cancers. Herein, we report the design of a γ-AApeptide-based antibody-like peptidomimetic as a radiotracer for EGFR-targeted positron emission tomography (PET) imaging. A dimeric cyclic γ-AApeptide (<strong>D1</strong>) was designed by dimerizing a previously reported EGFR-binding peptidomimetic ligand, resulting in a 6-fold enhancement in binding affinity (<em>K</em><sub>d</sub> = 0.11 μM) compared to its monomeric counterpart (<strong>M1</strong>, <em>K</em><sub>d</sub> = 0.67 μM). Both ligands were conjugated with chelators and radiolabeled with <sup>64</sup>Cu to yield <strong>[</strong><sup><strong>64</strong></sup><strong>Cu]Cu-NOTA-M1</strong> (monomer) and <strong>[</strong><sup><strong>64</strong></sup><strong>Cu]Cu-DOTA-D1</strong> (dimer), respectively. In vivo PET imaging demonstrated that <strong>[</strong><sup><strong>64</strong></sup><strong>Cu]Cu-DOTA-D1</strong> achieved significantly higher tumor uptake than <strong>[</strong><sup><strong>64</strong></sup><strong>Cu]Cu-NOTA-M1</strong> in EGFR-positive tumor models (e.g., 10.83 ± 2.70 %ID/g vs 2.80 ± 0.72 %ID/g in U87 tumors at 4 h p.i.). Blocking and EGFR-negative control studies further confirmed the targeting specificity of <strong>[</strong><sup><strong>64</strong></sup><strong>Cu]Cu-DOTA-D1</strong>. Ex vivo biodistribution analysis showed consistent enhancement in tumor uptake (e.g., 7.94 ± 0.24 %ID/g vs 3.81 ± 0.44 %ID/g in U87 tumors at 48 h p.i.) for the dimeric tracer, accompanied by increased uptake in clearance organs. Overall, this work demonstrates that cyclic γ-AApeptides could serve as effective antibody-like peptidomimetics for EGFR targeting in vivo and provides a versatile strategy for developing peptidomimetic radiotracers for molecular imaging applications.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5704–5717"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149306040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overcoming Solubility and Aggregation: Water-Soluble Porphyrins in Modern Phototherapy 克服溶解度和聚集性:现代光疗中的水溶性卟啉
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-09-25 DOI: 10.1021/acs.molpharmaceut.6c00451
Gayathri M. P, Jotiba P. Powar, Balaji Babu
{"title":"Overcoming Solubility and Aggregation: Water-Soluble Porphyrins in Modern Phototherapy","authors":"Gayathri M. P,&nbsp;Jotiba P. Powar,&nbsp;Balaji Babu","doi":"10.1021/acs.molpharmaceut.6c00451","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00451","url":null,"abstract":"<p>Photodynamic therapy (PDT) is a minimally invasive cancer treatment that works through the combined use of photosensitizers (PS), light, and molecular oxygen to generate reactive oxygen species. Several porphyrin-based photosensitizers have been clinically developed for PDT, with Photofrin being one of the most commonly used photosensitizers for tumor destruction. Several of the limitations associated with using porphyrins as photodynamic therapeutic agents include weak absorption in the therapeutic window, prolonged skin phototoxicity after photosensitizer administration, and variable composition. Porphyrins remain among the most extensively studied classes of PSs for PDT and aPDT (antimicrobial photodynamic therapy) because of their favorable photophysical characteristics. However, many photosensitizers have limited utility because of poor water solubility, aggregation in biological media, or suboptimal cellular uptake. In response to these challenges, recent efforts have increasingly emphasized rational molecular design to improve intrinsic water solubility while simultaneously enhancing their therapeutic performance. Although significant progress has been made with nanomaterials and hybrid systems, discrete water-soluble porphyrins remain a valuable molecular basis for the development of photosensitizers for both PDT and aPDT. Recent work on water-soluble porphyrin-based photosensitizers is discussed in the context of PDT, antimicrobial PDT, and selected theranostic applications, with emphasis on emerging strategies for their further development.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5163–5196"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149306015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Engineered Glatiramoid Peptides Emulate Glatiramer Acetate Activity in Solid Tumors 工程类格拉替胺肽模拟醋酸格拉替胺在实体肿瘤中的活性
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-09-29 DOI: 10.1021/acs.molpharmaceut.6c00718
Michelle Oti-Bronya, Huan Gong, Anirban Das, Elise M. Brown, Henry M. Zutter, J. Daniel Griffin, Cory Berkland, Jai S. Rudra
{"title":"Engineered Glatiramoid Peptides Emulate Glatiramer Acetate Activity in Solid Tumors","authors":"Michelle Oti-Bronya,&nbsp;Huan Gong,&nbsp;Anirban Das,&nbsp;Elise M. Brown,&nbsp;Henry M. Zutter,&nbsp;J. Daniel Griffin,&nbsp;Cory Berkland,&nbsp;Jai S. Rudra","doi":"10.1021/acs.molpharmaceut.6c00718","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00718","url":null,"abstract":"<p>Glatiramer acetate (GA) is a heterogeneous mixture of peptides that we have previously explored as an intratumoral immunomodulator. However, its chemical complexity complicates the mechanistic interpretation and rational design. In this study, we evaluated a set of sequence-defined “glatiramoid” peptides engineered to preserve the amino acid composition while varying the primary sequence. Biophysical characterization by circular dichroism, fluorescence spectroscopy, and transmission electron microscopy revealed sequence-dependent differences in supramolecular organization without pronounced changes in the secondary structure. Treatment of murine bone marrow-derived dendritic cells with these peptides produced distinct innate cytokine and chemokine secretion profiles, suggesting that sequence order influences immune signaling outcomes <em>in vitro</em>. In the CT26 mouse model of colon carcinoma, intratumoral administration of selected glatiramoid peptides in combination with anti-PD-1 therapy produced tumor growth responses that were not statistically distinguishable from those of commercial GA formulations. Systemic cytokine levels measured at study termination were generally lower for the sequence-defined peptide relative to GA. Together, these findings indicate that sequence-defined glatiramoid peptides reproduce selected GA-like biophysical and immunomodulatory properties. Further studies are required to establish their mechanisms of action, intratumoral behavior, and therapeutic contribution to checkpoint blockade.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5596–5608"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149306030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiosynthesis and Preclinical Evaluation of Enantiopure (R)‑[18F]Fluorolactate for PET Imaging of Metabolic Processes 对映纯(R)-[18F]氟乳酸酯用于代谢过程PET成像的放射合成和临床前评价。
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-07-25 DOI: 10.1021/acs.molpharmaceut.6c00236
Xiaoqing Zhuang, Jenni Virta, Negar A. Samani, Tomi T. Airenne, Maxwell W. G. Miner, Heidi Liljenbäck, Aino Latva-Rasku, Mitra Gerami, Jesse Ponkamo, Nea Läpinen, Pyry Dillemuth, Johan Rajander, Tiina A. Salminen, Sven Enerbäck, Pirjo Nuutila, Xiang-Guo Li, Anne Roivainen
{"title":"Radiosynthesis and Preclinical Evaluation of Enantiopure (R)‑[18F]Fluorolactate for PET Imaging of Metabolic Processes","authors":"Xiaoqing Zhuang,&nbsp;Jenni Virta,&nbsp;Negar A. Samani,&nbsp;Tomi T. Airenne,&nbsp;Maxwell W. G. Miner,&nbsp;Heidi Liljenbäck,&nbsp;Aino Latva-Rasku,&nbsp;Mitra Gerami,&nbsp;Jesse Ponkamo,&nbsp;Nea Läpinen,&nbsp;Pyry Dillemuth,&nbsp;Johan Rajander,&nbsp;Tiina A. Salminen,&nbsp;Sven Enerbäck,&nbsp;Pirjo Nuutila,&nbsp;Xiang-Guo Li,&nbsp;Anne Roivainen","doi":"10.1021/acs.molpharmaceut.6c00236","DOIUrl":"10.1021/acs.molpharmaceut.6c00236","url":null,"abstract":"<p>L-Lactate is a key substrate in energy metabolism and a potential biomarker for cancer and metabolic disorders. We developed an enantiomerically pure positron emission tomography (PET) tracer, (<em>R</em>)-[<sup>18</sup>F]fluorolactate, to mimic natural L-lactate. (<em>R</em>)-[<sup>18</sup>F]Fluorolactate was synthesized via nucleophilic ring-opening of benzyl (<em>S</em>)-oxirane-2-carboxylate, optimized to yield &gt;91% radiochemical purity, &gt; 95% enantiomeric excess, pH 6, and &gt;5.56 GBq/μmol molar activity. PET/computed tomography (CT) imaging, biodistribution, autoradiography, and stability analyses were conducted in fasted and nonfasted rats and in mice bearing subcutaneous Lewis lung carcinoma (LLC) tumors. In rats, tracer uptake was highest in the kidneys and liver, with fasting further increasing renal and hepatic uptake. In mice, (<em>R</em>)-[<sup>18</sup>F]fluorolactate accumulated in tumors. The monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 significantly reduced tracer uptake in normal tissues and LLC tumors, and increased renal excretion, confirming MCT1-mediated transport. More than 80% and 90% of the tracer remained intact in plasma at 70 min postinjection in rats and tumor-bearing mice, respectively. <em>In silico</em> structural analyses supported the experimental findings. (<em>R</em>)-[<sup>18</sup>F]Fluorolactate is a metabolically stable, MCT1-sensitive PET tracer suitable for noninvasive assessment of lactate transport and metabolism and shows promise for imaging MCT1-dependent lactate transport in cancer.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5305–5317"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148589502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preliminary Evaluation of Synthetic Amanitin Analogs as Novel Payloads for Potent Antibody−Drug Conjugates 合成Amanitin类似物作为新型有效抗体-药物偶联物的初步评价
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-10-04 DOI: 10.1021/acs.molpharmaceut.6c00708
Tuấn Trung Nguyễn, Juliette Froelich, Kayla C. Newell, Mihajlo Todorovic, David M. Perrin
{"title":"Preliminary Evaluation of Synthetic Amanitin Analogs as Novel Payloads for Potent Antibody−Drug Conjugates","authors":"Tuấn Trung Nguyễn,&nbsp;Juliette Froelich,&nbsp;Kayla C. Newell,&nbsp;Mihajlo Todorovic,&nbsp;David M. Perrin","doi":"10.1021/acs.molpharmaceut.6c00708","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00708","url":null,"abstract":"<p>Alpha-amanitin<span></span>the principal toxin of <em>Amanita phalloides</em>, infamous for its hepatotoxicity and lethality<span></span>has been receiving considerable attention as a candidate payload in antibody−drug conjugates (ADCs). Previously, we identified three synthetic amatoxins with heightened cytotoxicity against CHO, HEK 293, and HeLa cells. In this work, these analogs were advanced as ADC payloads using the well-established anti-HER2 antibody trastuzumab to provide a head-to-head comparative study against α-amanitin, where all payloads (synthetic or natural) are linked via a glutaric linker; esterification to the dihydroxy-isoleucine on the toxin and via an amide to an antibody lysine. Tested as ADC payloads, one synthetic amatoxin outperformed the natural toxin across various drug−antibody ratios (DARs) and across a panel of HER2-overexpressing cell lines; against SK-BR-3 cells, this ADC shows a 25-fold greater potency at DAR 2.1 compared to the same ADC linked to α-amanitin at DAR 2.0. At DAR values of 5−6, this toxin confers low-femtomolar IC<sub>50</sub> values on the corresponding trastuzumab conjugate when assayed against SK-BR-3 cells and shows exalted cytotoxicity against a panel of HER2-overexpressing cell lines compared to the ADC linked to α-amanitin.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5585–5595"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Experimental and Computational Characterization of Human Serum Albumin Recognition by Ga(III)-NOTA Dendrimer Nanomicelles with Distinct PET Biodistribution Profiles 具有不同PET生物分布特征的Ga(III)-NOTA树状纳米微粒识别人血清白蛋白的实验和计算表征
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-10-05 DOI: 10.1021/acs.molpharmaceut.6c01116
Anna Laura la Monaca, Gabriele Cavalieri, Domenico Marson, Tom Roussel, Ling Peng, Erik Laurini, Sabrina Pricl
{"title":"Experimental and Computational Characterization of Human Serum Albumin Recognition by Ga(III)-NOTA Dendrimer Nanomicelles with Distinct PET Biodistribution Profiles","authors":"Anna Laura la Monaca,&nbsp;Gabriele Cavalieri,&nbsp;Domenico Marson,&nbsp;Tom Roussel,&nbsp;Ling Peng,&nbsp;Erik Laurini,&nbsp;Sabrina Pricl","doi":"10.1021/acs.molpharmaceut.6c01116","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c01116","url":null,"abstract":"<p>We investigate the interaction of human serum albumin (HSA) with two Ga(III)-NOTA-functionalized amphiphilic dendrimers <strong>1</strong> and <strong>2</strong> that self-assemble into corresponding nanomicelles <strong>1@</strong> and <strong>2@</strong>, which were previously evaluated as positron emission tomography imaging nanoplatforms with distinct biodistribution profiles. These two nanosystems share the same Ga(III)-NOTA surface chemistry but differ in hydrophobic architecture and, consequently, in micellar stability. A combined physicochemical and computational workflow was used to quantify albumin binding, protein structural response, colloidal changes, and interfacial organization. Fluorescence quenching indicated HSA engagement by both nanomicelles, with a stronger perturbation of the Trp214 emission response for <strong>2@</strong>. Isothermal titration calorimetry confirmed this ranking, showing that HSA has higher apparent affinity for <strong>2@</strong> than for <strong>1@</strong> (<em>K</em><sub>d</sub> = 8.2 ± 3.8 μM and 39.4 ± 26.7 μM, respectively), with exothermic and thermodynamically favorable association in both cases. Analysis of the integrated heat profiles supported apparent compositions of approximately three HSA molecules per <strong>1@</strong> micelle and four HSA molecules per <strong>2@</strong> micelle. Circular dichroism and three-dimensional fluorescence showed that HSA largely retains its α-helical structure and Trp214 microenvironment upon binding, whereas dynamic light scattering and zeta-potential measurements confirmed formation of protein-nanomicelle complexes. Enhanced-sampling simulations reproduced the preferred HSA loading states and suggested that <strong>2@</strong> promotes a broader Ga(III)-NOTA-rich interfacial network. These findings indicate that the internal hydrophobic architecture can modulate albumin recognition even when the nominal Ga(III)-NOTA surface chemistry is conserved, providing a plausible molecular explanation for the distinct biodistribution behavior of these nanoprobes in biomedical imaging.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5914–5926"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel [67Cu]Cu-Labeled 4-p-(Tolyl)butyric Acid-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptides with Glycine and Polyethylene Glycol Linkers for Melanoma Targeting 新型[67Cu] cu标记的4-p-(托利基)丁酸共轭内酰胺环化α -黑色素细胞刺激激素肽与甘氨酸和聚乙二醇连接体用于黑色素瘤靶向
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-10-02 DOI: 10.1021/acs.molpharmaceut.6c01152
Zheng Qiao, Jingli Xu, Jing Wang, Megan Schulte, Fabio Gallazzi, Adrian F. Howansky, Wenchao Qu, Charles J. Smith, Yubin Miao
{"title":"Novel [67Cu]Cu-Labeled 4-p-(Tolyl)butyric Acid-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptides with Glycine and Polyethylene Glycol Linkers for Melanoma Targeting","authors":"Zheng Qiao,&nbsp;Jingli Xu,&nbsp;Jing Wang,&nbsp;Megan Schulte,&nbsp;Fabio Gallazzi,&nbsp;Adrian F. Howansky,&nbsp;Wenchao Qu,&nbsp;Charles J. Smith,&nbsp;Yubin Miao","doi":"10.1021/acs.molpharmaceut.6c01152","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c01152","url":null,"abstract":"&lt;p&gt;This study managed to examine how the 4-&lt;em&gt;p&lt;/em&gt;-(tolyl)butyric acid (&lt;em&gt;p&lt;/em&gt;-TBA) albumin binder and the aspartic acid linker affect the tumor targeting and biodistribution properties of [&lt;sup&gt;67&lt;/sup&gt;Cu]Cu-labeled &lt;em&gt;p&lt;/em&gt;-TBA-conjugated alpha-melanocyte-stimulating hormone (α-MSH) peptides. &lt;em&gt;p&lt;/em&gt;-TBA was attached to 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)-Lys-Gly-Gly-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-CONH&lt;sub&gt;2&lt;/sub&gt; (NOTA-Lys-GGNle-CycMSH&lt;sub&gt;hex&lt;/sub&gt;) and NOTA-Lys-PEG&lt;sub&gt;2&lt;/sub&gt;Nle-CycMSH&lt;sub&gt;hex&lt;/sub&gt; with or without the Asp linker to generate NOTA-Lys(&lt;em&gt;p&lt;/em&gt;-TBA/Asp-&lt;em&gt;p&lt;/em&gt;-TBA)-GGNle-CycMSH&lt;sub&gt;hex&lt;/sub&gt; and NOTA-Lys(&lt;em&gt;p&lt;/em&gt;-TBA/Asp-&lt;em&gt;p&lt;/em&gt;-TBA)-PEG&lt;sub&gt;2&lt;/sub&gt;Nle-CycMSH&lt;sub&gt;hex&lt;/sub&gt;. The melanocortin-1 receptor (MC1R) binding affinities of the designed peptides were determined on B16/F10 melanoma cells. The biodistribution properties of [&lt;sup&gt;67&lt;/sup&gt;Cu]Cu-NOTA-Lys(&lt;em&gt;p&lt;/em&gt;-TBA/Asp-&lt;em&gt;p&lt;/em&gt;-TBA)-GGNle-CycMSH&lt;sub&gt;hex&lt;/sub&gt; and [&lt;sup&gt;67&lt;/sup&gt;Cu]Cu-NOTA-Lys(&lt;em&gt;p&lt;/em&gt;-TBA/Asp-&lt;em&gt;p&lt;/em&gt;-TBA)-PEG&lt;sub&gt;2&lt;/sub&gt;Nle-CycMSH&lt;sub&gt;hex&lt;/sub&gt; were evaluated on B16/F10 melanoma-bearing C57BL/6 mice at 2 h post-injection to select a lead peptide. Then, the melanoma targeting and imaging properties of [&lt;sup&gt;67&lt;/sup&gt;Cu]Cu-NOTA-Lys(Asp-&lt;em&gt;p&lt;/em&gt;-TBA)-PEG&lt;sub&gt;2&lt;/sub&gt;Nle-CycMSH&lt;sub&gt;hex&lt;/sub&gt; were determined on B16/F10 melanoma-bearing C57BL/6 mice. The IC&lt;sub&gt;50&lt;/sub&gt; values of NOTA-Lys(&lt;em&gt;p&lt;/em&gt;-TBA/Asp-&lt;em&gt;p&lt;/em&gt;-TBA)-GGNle-CycMSH&lt;sub&gt;hex&lt;/sub&gt; and NOTA-Lys(&lt;em&gt;p&lt;/em&gt;-TBA/Asp-&lt;em&gt;p&lt;/em&gt;-TBA)-PEG&lt;sub&gt;2&lt;/sub&gt;Nle-CycMSH&lt;sub&gt;hex&lt;/sub&gt; were 0.26 ± 0.04, 0.54 ± 0.03, 0.46 ± 0.08, and 0.32 ± 0.04 nM, respectively. [&lt;sup&gt;67&lt;/sup&gt;Cu]Cu-NOTA-Lys(Asp-&lt;em&gt;p&lt;/em&gt;-TBA)-PEG&lt;sub&gt;2&lt;/sub&gt;Nle-CycMSH&lt;sub&gt;hex&lt;/sub&gt; was selected as a lead peptide due to its highest tumor/kidney and tumor/liver uptake ratios among the [&lt;sup&gt;67&lt;/sup&gt;Cu]Cu-peptides at 2 h post-injection. The B16/F10 melanoma uptake of [&lt;sup&gt;67&lt;/sup&gt;Cu]Cu-NOTA-Lys(Asp-&lt;em&gt;p&lt;/em&gt;-TBA)-PEG&lt;sub&gt;2&lt;/sub&gt;Nle-CycMSH&lt;sub&gt;hex&lt;/sub&gt; was 29.31 ± 3.22, 39.05 ± 1.38, 25.07 ± 2.03, and 11.77 ± 1.61% ID/g at 0.5, 2, 4, and 24 h post-injection, respectively. The B16/F10 melanoma lesions were clearly visualized by SPECT/CT using [&lt;sup&gt;67&lt;/sup&gt;Cu]Cu-NOTA-Lys(Asp-&lt;em&gt;p&lt;/em&gt;-TBA)-PEG&lt;sub&gt;2&lt;/sub&gt;Nle-CycMSH&lt;sub&gt;hex&lt;/sub&gt; as an imaging probe at 2 h post-injection. The utilization of &lt;em&gt;p&lt;/em&gt;-TBA as an albumin binder prolonged the blood circulation and enhanced the tumor uptake of [&lt;sup&gt;67&lt;/sup&gt;Cu]Cu-Asp-&lt;em&gt;p&lt;/em&gt;-TBA-PEG as compared to [&lt;sup&gt;67&lt;/sup&gt;Cu]Cu-NOTA-PEG&lt;sub&gt;2&lt;/sub&gt;Nle-CycMSH&lt;sub&gt;hex&lt;/sub&gt; without an albumin-binding moiety. The Asp linker expedited the blood clearance of [&lt;sup&gt;67&lt;/sup&gt;Cu]Cu-Asp-&lt;em&gt;p&lt;/em&gt;-TBA-PEG as compared to [&lt;sup&gt;67&lt;/sup&gt;Cu]Cu-&lt;em&gt;p&lt;/em&gt;-TBA-PEG. The combination of &lt;em&gt;p&lt;/em&gt;-TBA, Asp, and PEG linkers resulted in the highest tumor/blood, tumor/kidney, and tumor/liver uptake ratios of [&lt;sup&gt;67&lt;/sup&gt;Cu]Cu-Asp-&lt;em&gt;p&lt;/em&gt;-TBA-PEG among the designed [&lt;sup&gt;67&lt;/sup&gt;","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5927–5935"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书